10 completed, 4 unknown, 3 terminated, 2 active not recruiting. 12 Phase 3, 5 Phase 4, 4 Phase 1, 2 Phase 2.
Follow Buserelin: new trials by email Literature Review of Buserelin trials Research Report on Buserelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 2050 | 2021-12-06 | 2026-08-17 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation Buseralin, Placebo, pregnyl - Infertility | Phase 4 | Completed | Mount Sinai Hospital, Canada | 276 | 2016-03-01 | 2022-04-28 |
| Efficacy of Ovarian Stimulation Based on FSHR Genotype Status follicle stimulating hormone - Sterility | Phase 3 | Suspended | Medical University of Vienna | 165 | 2015-05-01 | 2015-05-05 |
| Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide - Non Castrate Metastatic Prostate Cancer | Phase 1 | Terminated | Institut Paoli-Calmettes | 6 | 2014-10-01 | 2017-11-17 |
| Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles rFSH, buserelin - In Vitro Fertilization, Ovarian Stimulation | Phase 4 | Terminated | Andros Day Surgery Clinic | 194 | 2013-03-01 | 2016-12-23 |
| The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol ghrh antagonist (cetrotide/orgalutran), gnrh agonist (suprefact) - Embryo's Genetic and Chromosomal Quality | Phase 3 | Unknown | European Hospital | 200 | 2012-09-01 | 2012-07-10 |
| Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer GnRH agonist, Anti-androgen, TAK-700 - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 239 | 2012-05-01 | 2026-03-06 |
| Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Radiation, Androgen Suppression Therapy - Prostate Cancer | Phase 3 | Recruiting | Proton Collaborative Group | 192 | 2012-01-01 | 2026-09-29 |
| Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer bicalutamide, flutamide, LHRH agonist (antagonist) therapy - Prostate Cancer | Phase 3 | Completed | Radiation Therapy Oncology Group | 1538 | 2009-09-01 | 2026-03-06 |
| Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare up Protocol in Poor Responders clomiphene citrate, buserelin - Pregnancy | Phase 4 | Completed | Yazd Medical University | 159 | 2009-04-01 | 2010-10-01 |
| Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Buserelin and Pregnyl, Pregnyl - OHSS (Ovarian Hyperstimulation) | Phase 4 | Completed | Regionshospitalet Viborg, Skive | 384 | 2009-01-01 | 2013-11-27 |
| Replacement of Fresh Embryo Transfers (ETs) by Frozen Embryo Transfers (FETs) Using Vitrification freezing embryos by vitrification, fresh embryo transfers, buserelin - In Vitro Fertilization | Phase 1 / Phase 2 | Unknown | Yazd Research & Clinical Center for Infertility | 500 | 2008-08-01 | 2010-01-20 |
| Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer bicalutamide, buserelin, flutamide - Prostate Cancer | Phase 3 | Terminated | NCIC Clinical Trials Group | 48 | 2008-06-02 | 2023-08-04 |
| Antagonist/Letrozole in Poor Responders letrozole, oral contraceptive (Marvelone), GnRH agonist (buserelin) - Ovarian Stimulation | Phase 1 / Phase 2 | Completed | Yazd Research & Clinical Center for Infertility | 120 | 2008-06-01 | 2013-12-23 |
| Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH ganirelix, suprefact - Infertility | Phase 3 | Unknown | Yazd Research & Clinical Center for Infertility | 2 | 2008-03-01 | 2009-01-15 |
| Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer PBRT, PLNRT, AA - Prostate Cancer | Phase 3 | Unknown | Radiation Therapy Oncology Group | 1792 | 2008-02-01 | 2025-05-09 |
| Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist clomiphene citrate, Ultrasound, GnRH antagonist - Ovarian Stimulation | Phase 4 | Completed | Yazd Research & Clinical Center for Infertility | 200 | 2008-01-01 | 2009-01-28 |
| Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer buserelin, custirsen sodium, flutamide - Prostate Cancer | Phase 1 | Completed | NCIC Clinical Trials Group | 25 | 2002-12-10 | 2023-08-04 |
| Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer bicalutamide, buserelin, cyproterone acetate - Prostate Cancer | Phase 3 | Completed | NCIC Clinical Trials Group | 1386 | 1999-01-05 | 2021-06-23 |
Showing 20 of 21. Sign in to see all of them.
Prostatic Neoplasms (9) · Infertility (3) · Ovarian Hyperstimulation Syndrome (1)
NCIC Clinical Trials Group (4) · Yazd Research & Clinical Center for Infertility (4) · Radiation Therapy Oncology Group (3) · NRG Oncology (2) · Andros Day Surgery Clinic (1) · European Hospital (1) · Institut Paoli-Calmettes (1) · Medical University of Vienna (1) · Mount Sinai Hospital, Canada (1) · Proton Collaborative Group (1) · Regionshospitalet Viborg, Skive (1) · Yazd Medical University (1)
Canada (10) · United States (6) · Iran (5) · Italy (2) · Austria (1) · China (1) · Denmark (1) · France (1) · Israel (1)
Kim N. Chi, MD (2) · Alan Pollack, MD, PhD (1) · Alvaro A. Martinez, MD, FACR (1) · Carlos Vargas, MD (1) · Celestia S. Higano, MD (1) · Johannes C. Huber, MD, PhD (1) · Laurence H. Klotz, MD (1) · M. Dror Michaelson, MD, PhD (1) · Malcolm D. Mason, MD (1) · Mehri Mashayekhy, infertility fellowship (1) · Michael R. McKenzie, MD, FRCPC (1) · Neil B Desai (1) · Padraig R. Warde, MB, MRCPI, FRCPC (1) · Patricia Lillis-Hearne, MD (1)
PMID 16145049, PMID 20373015, PMID 22056152, PMID 22931259, PMID 23753114, PMID 25691677, PMID 25732157, PMID 26014295, PMID 32563188, PMID 33390282, PMID 35569466, PMID 37104748, PMID 38212582
U10CA180868 (2)